摘要
目的:观察芪杉胶囊对肺癌A549细胞PI3KAKt信号通路的影响。方法:分别运用MTT法检测含药血清对A549细胞增殖的影响;Annexin V-PE/7-AAD双染法检测含药血清对A549细胞凋亡的影响;Western-blot法检测含药血清对A549细胞凋亡相关蛋白表达的影响;RT-PCR法检测含药血清对A549细胞凋亡相关基因表达的影响。结果:芪杉胶囊含药血清高、中、低剂量组分别作用于A549细胞时,均表现为抑制细胞增殖作用,其抑制率分别为24.26%,16.44%和10.89%,含药血清浓度越大,对细胞的抑制作用越显著。与空白组相比,芪杉胶囊含药血清高、中、低剂量组及顺铂组细胞凋亡率显著升高,且含药血清浓度越大,对细胞凋亡的作用越显著。芪杉胶囊含药血清高、中、低剂量组及顺铂组Caspase-3、Caspase-9、Cytochrome c、AKT、m TOR及PI3K蛋白和基因相对表达量与空白组相比,表达量降低,且含药血清浓度越大,对A549细胞凋亡相关蛋白和基因表达的影响越显著。结论:芪杉胶囊通过影响A549细胞凋亡相关Caspase-3、Caspase-9、Cytochrome c、AKT、m TOR及PI3K蛋白和基因表达,从而抑制细胞增值、促进细胞凋亡。
Objective: To observe the effect of Qishan Capsule on PI3KAKt signaling pathway in lung cancer A549 cells.Methods: The proliferation and apoptosis of A549 cells intervend with medicated serum were detected by MTT method and Annexin V-PE/7-AAD double staining method respectively. Protein and gene expressions related to apoptosis of A549 cells were tested by Western-blot assay and RT-PCR assay. Results: It is found out that different concentration of serum contaning Qishan Capsule had inhibiting effect on the proliferation of A549 cells; the inhibition rate was 24. 26%,16. 44% and 10. 89%,the higher concentration of the serum was,the more significant inhibitory effect it had on the proliferation of A549 cells. In terms of apoptosis rate,it was significantly increased in serum-Qishan Capsule groups and in cisplatin group,compared to that in the blank control group; the higher concentration of the serum was,the more significant effect it had on apoptosis. In terms of expressions of Caspase-3,Caspase-9,Cytochrome C,AKT,m TOR and PI3K,they were significantly decreased in serum-Qishan Capsule groups and in cisplatin group,compared to those in the blank control group; the higher concentration of the serum was,the more significant decrease was seen on the expressions. Conclusion: Qishan Capsule can inhibit the proliferation and promote apoptosis of A549 cells by regulating the expressions of Caspase-3,Caspase-9,Cytochrome C,AKT,mTOR and PI3 K.
作者
隋雨桐
迟文成
姜家康
SUI Yutong;CHI Wencheng;JIANG Jiakang(The First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150040,China)
出处
《中医药学报》
CAS
2018年第4期22-27,共6页
Acta Chinese Medicine and Pharmacology
基金
黑龙江省自然科学基金面上项目(H201478)